WCA Recommendations for the Long-Term Treatment of Panic Disorder

CNS Spectrums

Volumn 8, Issue 8 SUPPL. 1, 2003, Pages 17-30

  Pollack, Mark H ^a   Allgulander, Christer ^b   Bandelow, Borwin ^b   Cassano, Giovanni B ^b   Greist, John H ^b   Hollander, Eric ^b   Nutt, David J ^b   Okasha, Ahmed ^b   Swinson, Richard P ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADINAZOLAM; ALPRAZOLAM; BENZODIAZEPINE DERIVATIVE; BROFAROMINE; CITALOPRAM; CLOMIPRAMINE; CLONAZEPAM; DIAZEPAM; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; LOFEPRAMINE; LORAZEPAM; MAPROTILINE; MOCLOBEMIDE; MONOAMINE OXIDASE A INHIBITOR; MONOAMINE OXIDASE INHIBITOR; PAROXETINE; PINDOLOL; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT;

AGORAPHOBIA; ANTICHOLINERGIC EFFECT; ANXIETY DISORDER; AVOIDANCE BEHAVIOR; BEHAVIOR THERAPY; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE THERAPY; COMORBIDITY; CONFERENCE PAPER; DIARRHEA; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DISEASE PREDISPOSITION; DRUG APPROVAL; DRUG CHOICE; DRUG DEPENDENCE; DRUG EFFICACY; DRUG INDICATION; DRUG TOLERABILITY; DYSPEPSIA; EJACULATION DISORDER; EUROPE; EXERCISE; EXPOSURE BASED PSYCHOTHERAPY; HEALTH CARE UTILIZATION; HUMAN; INTERNATIONAL COOPERATION; LIBIDO DISORDER; LONG TERM CARE; MAINTENANCE THERAPY; MAJOR DEPRESSION; MOOD DISORDER; PANIC; PHOBIA; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; PSYCHOTHERAPY; SIDE EFFECT; SUICIDE; SYMPTOMATOLOGY; TREMOR; UNITED STATES; WORLD COUNCIL OF ANXIETY; XEROSTOMIA; ADULT; METHODOLOGY; MULTIMODALITY CANCER THERAPY; REVIEW;

ADULT; ANTIDEPRESSIVE AGENTS, TRICYCLIC; BENZODIAZEPINES; COGNITIVE THERAPY; COMBINED MODALITY THERAPY; DIAGNOSIS, DIFFERENTIAL; HUMANS; MONOAMINE OXIDASE INHIBITORS; PANIC DISORDER; SEROTONIN UPTAKE INHIBITORS;

EID: 1542319764     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/s109285290000691x     Document Type: Conference Paper

References (141)

1. Diagnostic and Statistical Manual of Mental Disorders. 3rd ed. Washington, DC: American Psychiatric Association; 1980.
2. Pollack MH, Marzol PC. Panic: course, complications and treatment of panic disorder. J Psychopharmacol. 2000;14:S25-S30.
3. Regier DA, Narrow WE, Rae DS. The epidemiology of anxiety disorders: the Epidemiologic Catchment Area (ECA) experience. J Psychiatr Res. 1990;24(suppl 2):3-14.
4. Shear MK, Clark D, Feske U. The road to recovery in panic disorder: response, remission, and relapse. J Clin Psychiatry. 1998;59(suppl 8):4-8.
5. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.
6. Carr RE. Panic disorder and asthma. J Asthma. 1999;36:143-152.
7. Gorman JM, Kent JM, Sullivan GM, et al. Neuroanatomical hypothesis of panic disorder, revised. Am J Psychiatry. 2000;157:493-505.
8. Fava GA, Mangelli L. Subclinical symptoms of panic disorder: new insights into pathophysiology and treatment. Psychother Psychosom. 1999;68:281-289.
9. Katschnig H, Amering M. The long-term course of panic disorder and its predictors. J Clin Psychopharmacol. 1998;18:6S-11S.
10. Weissman MM, Bland RC, Canino GJ, et al. The cross-national epidemiology of panic disorder. Arch Gen Psychiatry. 1997;54:305-309.
11. Cross-National Collaborative Panic Study SPI. Drug treatment of panic disorder. Comparative efficacy of alprazolam, imipramine, and placebo. Br J Psychiatry. 1992;160:191-202.
12. Katon WJ, Von Korff M, Lin E. Panic disorder: relationship to high medical utilization. Am J Med. 1992;92:7S-11S.
13. Kennedy BL, Schwab JJ. Utilization of medical specialists by anxiety disorder patients. Psychosomatics. 1997;38:109-112.
14. Fleet R, Lavoie K, Beitman BD. Is panic disorder associated with coronary artery disease? A critical review of the literature. J Psychosom Res. 2000;48:347-356.
15. Mukerji V, Beitman BD, Alpert MA. Chest pain and angiographically normal coronary arteries. Implications for treatment. Tex Heart Inst J. 1993;20:170-179.
16. Coryell W, Noyes R, Clancy J. Excess mortality in panic disorder. A comparison with primary unipolar depression. Arch Gen Psychiatry. 1982;39:701-703.
17. Weissman MM, Markowitz JS, Ouellette R, et al. Panic disorder and cardiovascular/cerebrovascular problems: results from a community survey. Am J Psychiatry. 1990;147:1504-1508.
18. Davies SJ, Ghahramani P, Jackson PR, et al. Association of panic disorder and panic attacks with hypertension. Am J Med. 1999;107:310-316.
19. Carr RE, Lehrer PM, Rausch LL, et al. Anxiety sensitivity and panic attacks in an asthmatic population. Behav Res Ther. 1994;32:411-418.
20. Eaton WW, Kessler RC, Wittchen HU, et al. Panic and panic disorder in the United States. Am J Psychiatry. 1994;151:413-420.
21. Lecrubier Y, Ustun TB. Panic and depression: a worldwide primary care perspective. Int Clin Psychopharmacol. 1998;13(suppl 4):S7-S11.
22. Johnson J, Weissman MM, Klerman GL. Panic disorder, comorbidity, and suicide attempts. Arch Gen Psychiatry. 1990;47:805-808.
23. Klerman GL, Weissman MM, Ouellette R, et al. Panic attacks in the community. Social morbidity and health care utilization. JAMA. 1991;265:742-746.
24. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-111-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry. 1994;51:8-19.
25. Wittchen HU, Essau CA, von Zerssen D, et al. Lifetime and six-month prevalence of mental disorders in the Munich Follow-Up Study. Eur Arch Psychiatry Clin Neurosci. 1992;241:247-258.
26. Katschnig H, Amering M, Stolk JM, et al. Long-term follow-up after a drug trial for panic disorder. Br J Psychiatry. 1995;167:487-494.
27. Keller MB, Yonkers KA, Warshaw MG, et al. Remission and relapse in subjects with panic disorder and panic with agoraphobia: a prospective short-interval naturalistic follow-up. J Nerv Ment Dis. 1994;182:290-296.
28. Stein MB, Tancer ME, Uhde TW. Major depression in patients with panic disorder: factors associated with course and recurrence. J Affect Disord. 1990;19:287-296.
29. Segui J, Marquez M, Garcia L, et al. Differential clinical features of early-onset panic disorder. J Affect Disord. 1999;54:109-117.
30. Yonkers KA, Zlotnick C, Allsworth J, et al. Is the course of panic disorder the same in women and men? AmJ Psychiatry. 1998;155:596-602.
31. Keller MB, Baker LA. The clinical course of panic disorder and depression. J Clin Psychiatry. 1992;53 (suppl):5-8.
32. Warshaw MG, Massion AO, Shea MT, et al. Predictors of remission in patients with panic with and without agoraphobia: prospective 5-year follow-up data. J Nerv Ment Dis. 1997;185:517-519.
33. Markowitz JS, Weissman MM, Ouellette R, et al. Quality of life in panic disorder. Arch Gen Psychiatry. 1989;46:984-992.
34. Ettigi P, Meyerhoff AS, Chirban JT, et al. The quality of life and employment in panic disorder. J Nerv Ment Dis. 1997;185:368-372.
35. Swinson RP, Cox BJ, Woszczyna CB. Use of medical services and treatment for panic disorder with agoraphobia and for social phobia. CMAJ. 1992;147:878-883
36. Weissman MM, Klerman GL, Markowitz JS, et al. Suicidal ideation and suicide attempts in panic disorder and attacks. N Engl J Med. 1989;321:1209-1214.
37. Cox BJ, Direnfeld DM, Swinson RP, et al. Suicidal ideation and suicide attempts in panic disorder and social phobia. Am J Psychiatry. 1994;151:882-887.
38. Henriksson MM, Isometsa ET, Kuoppasalmi KI, et al. Panic disorder in completed suicide. J Clin Psychiatry. 1996;57:275-281.
39. Lepine JP, Chignon JM, Teherani M. Suicide attempts in patients with panic disorder. Arch Gen Psychiatry. 1993;50:144-149.
40. Cowley DS, Flick SN, Roy-Byrne PP. Long-term course and outcome in panic disorder: a naturalistic follow-up study. Anxiety. 1996;2:13-21.
41. Ball SG, Otto MW, Pollack MH, et al. Predicting prospective episodes of depression in patients with panic disorder: a longitudinal study. J Consult Clin Psychol. 1994;62:359-365.
42. McElroy SL, Altshuler LL, Suppes T, et al. Axis I psychiatric comorbidity and its relationship to historical illness variables in 288 patients with bipolar disorder. Am J Psychiatry. 2001;158:420-426.
43. Stein MB, Tancer ME, Gelernter CS, et al. Major depression in patients with social phobia. Am J Psychiatry. 1990;147:637-639.
44. Aronson TA, Craig TJ. Cocaine precipitation of panic disorder. Am J Psychiatry. 1986;143:643-645.
45. Nutt DJ. Antidepressants in panic disorder: clinical and preclinical mechanisms. J Clin Psychiatry. 1998;59(suppl 8):24-28.
46. Bradwejn J, Koszycki D, Shriqui C. Enhanced sensitivity to cholecystokinin tetrapeptide in panic disorder. Clinical and behavioral findings. Arch Gen Psychiatry. 1991;48:603-610.
47. Klein E, Zohar J, Geraci MF, et al. Anxiogenic effects of m-CPP in patients with panic disorder: comparison to caffeine's anxiogenic effects. Biol Psychiatry. 1991;30:973-984.
48. den Boer JA, Westenberg HG. Effect of a serotonin and noradrenaline uptake inhibitor in panic disorder; a double-blind comparative study with fluvoxamine and maprotiline. Int Clin Psychopharmacol. 1988;3:59-74.
49. Norman TR, Gregory MS, Judd FK, et al. Platelet serotonin uptake in panic disorder: comparison with normal controls and the effect of treatment. Aust N Z J Psychiatry. 1988;22:390-395.
50. Charney DS, Heninger GR, Jatlow PI. Increased anxiogenic effects of caffeine in panic disorders. Arch Gen Psychiatry. 1985;42:233-243.
51. Guy W. ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education and Welfare publication (ADM) 76-338. Rockville, Md: National Institute of Mental Health; 1976:218-222.
52. Hamilton M. Diagnosis and rating of anxiety. Br J Psychiatry. 1969;3:76-79.
53. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56-62.
54. Sheehan DV. The Anxiety Disease. New York, NY: Bantam Books. 1983.
55. Argyle N, Deltito J, Allerup P, et al. The Panic-Associated Symptom Scale: measuring the severity of panic disorder. Acta Psychiatr Scand. 1991;83:20-26.
56. Bandelow B, Broocks A, Pekrun G, et al. The use of the Panic and Agoraphobia Scale (P & A) in a controlled clinical trial. Pharmacopsychiatry. 2000;33:174-181.
57. Klein DF, Fink M. Psychiatric reaction patterns to imipramine. Am J Psychiatry. 1962;119:432-438.
58. Bakish D, Hooper CL, Filteau MJ, et al. A double-blind placebo-controlled trial comparing fluvoxamine and imipramine in the treatment of panic disorder with or without agoraphobia. Psychopharmacol Bull. 1996;32:135-141.
59. Rizley R, Kahn RJ, McNair DM, et al. A comparison of alprazolam and imipramine in the treatment of agoraphobia and panic disorder. Psychopharmacol Bull. 1986;22:167-172.
60. Taylor CB, Hayward C, King R, et al. Cardiovascular and symptomatic reduction effects of alprazolam and imipramine in patients with panic disorder: results of a double-blind, placebo-controlled trial. J Clin Psychopharmacol. 1990;10:112-118.
61. Schweizer E, Rickels K, Weiss S, et al. Maintenance drug treatment of panic disorder. I. Results of a prospective, placebo-controlled comparison of alprazolam and imipramine. Arch Gen Psychiatry. 1993;50:51-60.
62. Andersch S, Rosenberg NK, Kullingsjo H, et al. Efficacy and safety of alprazolam, imipramine and placebo in treating panic disorder. A Scandinavian multicenter study. Acta Psychiatr Scand Suppl. 1991;365:18-27.
63. Leon CA, De Arango MV, Arevalo W, et al. Comparison of the effect of alprazolam, imipramine and placebo in the treatment of panic disorders in Cali, Colombia. Acta Psiquiatr Psicol Am Lat. 1990;36:59-72.
64. Barlow DH, Gorman JM, Shear MK, et al. Cognitive-behavioral therapy, imipramine, or their combination for panic disorder: a randomized controlled trial. JAMA. 2000;283:2529-2536.
65. Johnston DG, Troyer IE, Whitsett SF. Clomipramine treatment of agoraphobic women. An eight-week controlled trial. Arch Gen Psychiatry. 1988;45:453-459.
66. Fahy TJ, O'Rourke D, Brophy J, et al. The Galway Study of Panic Disorder. I: clomipramine and lofepramine in DSM III-R panic disorder: a placebo controlled trial. J Affect Disord. 1992;2563-2575.
67. Hoffart A, Due-Madsen J, Lande B, et al. Clomipramine in the treatment of agoraphobic inpatients resistant to behavioral therapy. J Clin Psychiatry. 1993;54:481-487.
68. Lecrubier Y, Bakker A, Dunbar G, et al. A comparison of paroxetine, clomipramine and placebo in the treatment of panic disorder. Collaborative Paroxetine Panic Study Investigators. Acta Psychiatr Scand. 1997;95:145-152.
69. Bakker A, van Dyck R, Spinhoven P, et al. Paroxetine, clomipramine, and cognitive therapy in the treatment of panic disorder. J Clin Psychiatry. 1999;60:831-838.
70. Wade AG, Lepola U, Koponen HJ, et al. The effect of citalopram in panic disorder. Br J Psychiatry. 1997;170:549-553.
71. Broocks A, Bandelow B, Pekrun G, et al. Comparison of aerobic exercise, clomipramine, and placebo in the treatment of panic disorder. Am J Psychiatry. 1998;155:603-609.
72. Modigh K, Westberg P, Eriksson E. Superiority of clomipramine over imipramine in the treatment of panic disorder: a placebo-controlled trial. J Clin Psychopharmacol. 1992;12:251-261.
73. Diagnostic and Statistical Manual of Mental Disorders. 3rd ed rev. Washington, DC: American Psychiatric Association; 1987.
74. Cassano GB, Petracca A, Perugi G, et al. Clomipramine for panic disorder: I. The first 10 weeks of a long-term comparison with imipramine. J Affect Disord. 1988;14:123-127.
75. Sheehan DV. Current concepts in the treatment of panic disorder. J Clin Psychiatry. 1999;60(suppl 18):16-21.
76. Ballenger JC, Davidson JR, Lecrubier Y, et al. Consensus statement on panic disorder from the International Consensus Group on Depression and Anxiety. J Clin Psychiatry. 1998;59(suppl 8):47-54.
77. Davidson JR. The long-term treatment of panic disorder. J Clin Psychiatry. 1998;59(suppl 8):17-21.
78. Ballenger JC, Wheadon DE, Steiner M, et al. Double-blind, fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder. Am J Psychiatry. 1998;155:36-42.
79. Oehrberg S, Christiansen PE, Behnke K, et al. Paroxetine in the treatment of panic disorder. A randomised, double-blind, placebo-controlled study. Br J Psychiatry. 1995;167:374-379.
80. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.
81. Stein MB, Ron NG, Walker JR, et al. Do selective serotonin re-uptake inhibitors enhance the efficacy of very brief cognitive behavioral therapy for panic disorder? A pilot study. Psychiatry Res. 2000;94:191-200.
82. Londborg PD, Wolkow R, Smith WT, et al. Sertraline in the treatment of panic disorder. A multi-site, double-blind, placebo-controlled, fixed-dose investigation. Br J Psychiatry. 1998;173:54-60.
83. Pohl RB, Wolkow RM, Clary CM. Sertraline in the treatment of panic disorder: a double-blind multicenter trial. Am J Psychiatry. 1998;155:1189-1195.
84. Pollack MH, Otto MW, Worthington JJ, et al. Sertraline in the treatment of panic disorder: a flexible-dose multicenter trial. Arch Gen Psychiatry. 1998;55:1010-1016.
85. Pollack MH, Rapaport MH, Clary CM, Mardekian J, Wolkow R. Sertraline treatment of panic disorder: response in patients at risk for poor outcome. J Clin Psychiatry. 2000;61:922-927.
86. Hoehn-Saric R, McLeod DR, Hipsley PA. Effect of fluvoxamine on panic disorder. J Clin Psychopharmacol. 1993;13:321-326.
87. Black DW, Wesner R, Bowers W, et al. A comparison of fluvoxamine, cognitive therapy, and placebo in the treatment of panic disorder. Arch Gen Psychiatry. 1993;50:44-50.
88. Sharp DM, Power KG, Simpson RJ, et al. Global measures of outcome in a controlled comparison of pharmacological and psychological treatment of panic disorder and agoraphobia in primary care. Br J Gen Pract. 1997;47:150-155.
89. de Beurs E, van Balkom AJ, Lange A, et al. Treatment of panic disorder with agoraphobia: comparison of fluvoxamine, placebo, and psychological panic management combined with exposure and of exposure in vivo alone. Am J Psychiatry. 1995;152:683-691.
90. Michelson D, Lydiard RB, Pollack MH, et al. Outcome assessment and clinical improvement in panic disorder: evidence from a randomized controlled trial of fluoxetine and placebo. The Fluoxetine Panic Disorder Study Group. Am J Psychiatry. 1998;155:1570-1577.
91. Hirschmann S, Dannon PN, lancu I, et al. Pindolol augmentation in patients with treatment-resistant panic disorder: a double-blind, placebo-controlled trial. J Clin Psychopharmacol. 2000;20:556-559
92. Rickels K, Schweizer E, Weiss S, et al. Maintenance drug treatment for panic disorder. II. Short- and long-term outcome after drug taper. Arch Gen Psychiatry. 1993;50:61-68.
93. den Boer JA. Pharmacotherapy of panic disorder: differential efficacy from a clinical viewpoint. J Clin Psychiatry. 1998;59(suppl 8):30-36.
94. Ballenger JC, Burrows GD, DuPont RL, et al. Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. I. Efficacy in short-term treatment. Arch Gen Psychiatry. 1988;45:413-422.
95. Pecknold JC, Swinson RP, Kuch K, et al. Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. III. Discontinuation effects. Arch Gen Psychiatry. 1988;45:429-436.
96. Lydiard RB, Lesser IM, Ballenger JC, et al. A fixed dose study of alprazolam 2 mg, alprazolam 6 mg, and placebo in panic disorder. J Clin Psychopharmacol. 1992;12:96-103.
97. Marks IM, Swinson RP, Basoglu M, et al. Alprazolam and exposure alone and combined in panic disorder with agoraphobia. A controlled study in London and Toronto. Br J Psychiatry. 1993;162:776-787.
98. Beauclair L, Fontaine R, Annable L, et al. Clonazepam in the treatment of panic disorder: a double-blind, placebo-controlled trial investigating the correlation between clonazepam concentrations in plasma and clinical response. J Clin Psychopharmacol. 1994;14:111-118.
99. Rosenbaum JF, Moroz G, Bowden CL. Clonazepam in the treatment of panic disorder with or without agoraphobia: a dose-response study of efficacy, safety, and discontinuance. Clonazepam Panic Disorder Dose-Response Study Group. J Clin Psychopharmacol. 1997;17:390-400.
100. Moroz G, Rosenbaum JF. Efficacy, safety, and gradual discontinuation of clonazepam in panic disorder: a placebo-controlled, multicenter study using optimized dosages. J Clin Psychiatry. 1999;60:604-612.
101. Valenca AM, Nardi AE, Nascimento I, et al. Double-blind clonazepam vs placebo in panic disorder treatment. Arq Neuropsiquiatr. 2000;58:1025-1029.
102. Tesar GE, Rosenbaum JF, Pollack MH, et al. Double-blind, placebo-controlled comparison of clonazepam and alprazolam for panic disorder. J Clin Psychiatry. 1991;52:69-76.
103. Noyes R, Burrows GD, Reich JH, et al. Diazepam versus alprazolam for the treatment of panic disorder. J Clin Psychiatry. 1996;57:349-355.
104. Dunner DL, Ishiki D, Avery DH, et al. Effect of alprazolam and diazepam on anxiety and panic attacks in panic disorder: a controlled study. J Clin Psychiatry. 1986;47:458-460.
105. Charney DS, Woods SW. Benzodiazepine treatment of panic disorder: a comparison of alprazolam and lorazepam. J Clin Psychiatry. 1989;50:418-423.
106. Schweizer E, Fox I, Case G, et al. Lorazepam vs. alprazolam in the treatment of panic disorder. Psychopharmacol Bull. 1988;24:224-227.
107. Schweizer E, Pohl R, Balon R, et al. Lorazepam vs. alprazolam in the treatment of panic disorder. Pharmacopsychiatry. 1990;23:90-93.
108. Sheehan DV, Ballenger J, Jacobsen G. Treatment of endogenous anxiety with phobic, hysterical, and hypochondriacal symptoms. Arch Gen Psychiatry. 1980;37:51-59.
109. van Vliet IM, Westenberg HG, den Boer JA. MAO inhibitors in panic disorder: clinical effects of treatment with brofaromine. A double blind placebo controlled study. Psychopharmacology (Berl). 1993;112:483-489.
110. van Vliet IM, den Boer JA, Westenberg HG, et al. A doubleblind comparative study of brofaromine and fluvoxamine in outpatients with panic disorder. J Clin Psychopharmacol. 1996;16:299-306.
111. Bakish D, Saxena BM, Bowen R, et al. Reversible monoamine oxidase-A inhibitors in panic disorder. Clin Neuropharmacol. 1993;16(suppl 2):S77-S82.
112. Loerch B, Graf-Morgenstern M, Hautzinger M, et al. Randomised placebo-controlled trial of moclobemide, cognitive-behavioural therapy and their combination in panic disorder with agoraphobia. Br J Psychiatry. 1999;174:205-212.
113. Tiller JW, Bouwer C, Behnke K. Moclobemide and fluoxetine for panic disorder. International Panic Disorder Study Group. Eur Arch Psychiatry Clin Neurosci. 1999;249(suppl 1):S7-S10.
114. Lydiard RB, Steiner M, Burnham D, et al. Efficacy studies of paroxetine in panic disorder. Psychopharmacol Bull. 1998;34:175-182.
115. Lecrubier Y, Judge R. Long-term evaluation of paroxetine, clomipramine and placebo in panic disorder. Collaborative Paroxetine Panic Study Investigators. Acta Psychiatr Scand. 1997;95:153-160.
116. Rapaport M, Walkow R, Rubin A, et al. Sertraline treatment of panic disorder: results of a long-term study. Acta Psychiatr Scand. 2001;104(4):289-98.
117. Michelson D, Pollack M, Lydiard RB, et al. Continuing treatment of panic disorder after acute response: randomised, placebo-controlled trial with fluoxetine. The Fluoxetine Panic Disorder Study Group. Br J Psychiatry. 1999;174:213-218.
118. Lepola UM, Wade AG, Leinonen EV, et al. A controlled, prospective, 1-year trial of citalopram in the treatment of panic disorder. J Clin Psychiatry. 1998;59:528-534.
119. Mavissakalian MR, Perel JM. 2nd year maintenance and discontinuation of imipramine in panic disorder with agoraphobia. Ann Clin Psychiatry. 2001;13:63-67.
120. Lepola UM, Rimon RH, Riekkinen PJ. Three-year follow-up of patients with panic disorder after short-term treatment with alprazolam and imipramine. Int Clin Psychopharmacol. 1993;8:115-118.
121. Lepola U, Koponen H, Leinonen E. A naturalistic 6-year follow-up study of patients with panic disorder. Acta Psychiatr Scand. 1996;93:181-183.
122. Curtis GC, Massana J, Udina C, et al. Maintenance drug therapy of panic disorder. J Psychiatr Res. 1993;27(suppl 1):127-142.
123. Clark DM, Salkovskis PM, Hackmann A, et al. A comparison of cognitive therapy, applied relaxation and imipramine in the treatment of panic disorder. BrJ Psychiatry. 1994;164:759-769.
124. Lotufo-Neto F, Bernik M, Ramos RT, et al. A dose-finding and continuation study of clomipramine in panic disorder. J Psychopharmacology. 2001;15:13-17.
125. de Beurs E, van Balkom AJ, van Dyck R, et al. Long-term outcome of pharmacological and psychological treatment for panic disorder with agoraphobia: a 2-year naturalistic follow-up. Acta Psychiatr Scand. 1999;99:59-67.
126. Pohl R, Holland P, Chung H, Clary C. Effectiveness of sertraline in long-term treatment of panic disorder: treatment response, quality of life, and sexual functioning. Poster presented at: the American Psychiatric Association Annual Meeting, 2001; New Orleans, LA.
127. Arato M, Lepola U, Austin C. Sertraline vs imipramine treatment of comorbid panic disorder and major depression. Poster presented at: the American Psychiatric Association annual meeting,; May 2001; New Orleans, LA.
128. Saiz Ruiz J, Gomez Beneyto M, Gutierrez Casares JR, et al. Sertraline in the treatment of panic disorder: a naturalistic study. Poster presented at: the American Psychiatric Association Annual Meeting; May 2001; New Orleans, LA.
129. Roy-Byme PP, Clary CM, Miceli RJ, Colucci SV, Xu Y, Grudzinski AN. The effect of selective serotonin reuptake inhibitor treatment of panic disorder on emergency room and laboratory resource utilization. J Clin Psychiatry. 2001;62:678-682.
130. Leinonen E, Lepola U, Koponen H, et al. Citalopram controls phobic symptoms in patients with panic disorder: randomized controlled trial. J Psychiatry Neurosci. 2000;25:25-32.
131. Pollack MH, Otto MW, Tesar GE, et al. Long-term outcome after acute treatment with alprazolam or clonazepam for panic disorder. J Clin Psychopharmacol. 1993;13:257-263.
132. Brown TA, Barlow DH. Long-term outcome in cognitive-behavioral treatment of panic disorder: clinical predictors and alternative strategies for assessment. J Consult Clin Psychol. 1995;63:754-765.
133. Gelder MG. Combined pharmacotherapy and cognitive behavior therapy in the treatment of panic disorder. J Clin Psychopharmacol. 1998;18:2S-5S.
134. American Psychiatric Association. Practice guidelines for the treatment of patients with panic disorder. Am J Psychiatry. 1998;155:1-34.
135. Wiborg IM, Dahl AA. Does brief dynamic psychotherapy reduce the relapse rate of panic disorder? Arch Gen Psychiatry. 1996;53:689-694.
136. Mavissakalian M, Michelson L. Agoraphobia: relative and combined effectiveness of therapist-assisted in vivo exposure and imipramine. J Clin Psychiatry. 1986;47:117-122.
137. Zitrin CM, Klein DF, Woerner MG. Treatment of agoraphobia with group exposure in vivo and imipramine. Arch Gen Psychiatry. 1980;37:63-72.
138. Lecrubier Y. The impact of comorbidity on the treatment of panic disorder. J Clin Psychiatry. 1998;59(suppl 8):11-14.
139. Baldwin DS, Birtwistle J. The side effect burden associated with drug treatment of panic disorder. J Clin Psychiatry. 1998;5(suppl 8):39-44.
140. Roy-Byrne P, Stein M, Bystrisky A, et al. Pharmacotherapy of panic disorder: proposed guidelines for the family physician. J Am Board Fam Pract. 1998;11:282-290.
141. Anxiety Review Panel. Evans M, Bradwejn J, Dunn L, eds. Guidelines for the treatment of anxiety disorders in primary care. Toronto, Canada: Queen's Printer of Ontario; 2000. Available at: www.opot.org Accessed November 10, 2001.